Finance

Biotech Active Stocks: Arrowhead Research (NASDAQ:ARWR), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX), MannKind Corporation (NASDAQ:MNKD)

Arrowhead Research Corp (NASDAQ:ARWR) stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank in a report issued on Monday, American Banking News.com reports. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was -16.09% in last session and finished the day at $17.37. Traded volume was 7.56million shares in the last session and the average volume of the stock remained 1.44million shares. The beta of the stock remained 2.45. Arrowhead Research Corp (NASDAQ:ARWR) insider ownership is 1.10%.

Gilead Sciences Inc (NASDAQ: GILD ) Sovaldi, for instance, is able to cure some hepatitis C genotypes on its own, but requires help from other drugs for other genotypes. Fortunately, there’s a simple diagnostic to determine the genotype of the virus, making it easy for Gilead to show efficacy. Gilead Sciences, Inc. (NASDAQ:GILD) rose 0.08 percent to $72.13 Monday on volume of 29.29million shares. The intra-day range of the stock was $68.81 to $72.89. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $110.95billion.

Novavax Inc (NASDAQ:NVAX) major shareholder Pharmaceuticals Ltd Cadila sold 3,000,000 shares of the stock on the open market in a transaction dated Friday, March 21st. Novavax, Inc. (NASDAQ:NVAX)’s stock on Mar 24, 2014 reported a decrease of -11.75% to the closing price of $4.13. Its fifty two weeks range is $1.68 -$6.95. The total market capitalization recorded $963.40million. The overall volume in the last trading session was 13.73million shares. In its share capital, NVAX has 168.54million outstanding shares.

Shares of MannKind Corporation (NASDAQ:MNKD) were the recipient of some unusual options trading activity on Monday. Traders purchased 21,101 call options on the company, AnalystRatings.NET reports. This is an increase of approximately 105% compared to the average daily volume of 10,311 call options. On Monday, shares of MannKind Corporation (NASDAQ:MNKD) advanced 0.68% to close the day at $5.91. Company monthly performance is recorded as -1.83%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 19.88%.